clinical trial · NCT06487000
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
Atopic DermatitisEC-18Placebo EC-18
brief summary
To evaluate the efficacy and safety of oral administration of dose-dependent EC-18 for 16 weeks in patients with moderate to severe atopic dermatitis
started
May 1, 2025
primary completion
Oct 1, 2026
completion
Dec 1, 2026
last updated
Nov 8, 2024
detailed description
This study will utilize a randomized, double blind, placebo-controlled, parallel-group, multi-Center design. The Experimental group 1 will receive 1000mg of EC-18\[2 capsules of EC-18 500mg, 2 capsules of placebo\]. The experimental group 2 will receive 2000mg of EC-18 \[4 capsules of EC-18\]. The placebo group will receive 4 capsules of placebo. The time frame of this clinical trial will consist 16 weeks.
official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Phase 2 Clinical Trial to Evaluate Efficacy and Safety of EC-18 in Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol